EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn’s Disease Patients

Gerum Gashaw Gebeyehu, Giacomo Broglio, Eleanor Liu, Jimmy K Limdi, Christian Selinger, Joseph Fiske, Violeta Razanskaite, Philip J Smith, Paul K Flanagan, Sreedhar Subramanian iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae174 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Gerum Gashaw Gebeyehu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department Gastroenterology, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic therapies are associated with increased infection risk among elderly patients with inflammatory bowel disease (IBD). However, there are few data on the safety and effectiveness of ustekinumab compared with anti-tumor necrosis factor (anti-TNF) agents in the elderly.

Methods

The study sought to compare the safety and effectiveness of ustekinumab and anti-TNF agents in elderly Crohn’s disease (CD) patients. Patients ≥60 years of age who commenced ustekinumab or an anti-TNF agent for CD were included in this retrospective multicenter cohort. The primary outcome was incidence of serious infections requiring hospitalization. Effectiveness was assessed by clinical remission, clinical response, and treatment persistence rates at 6 months. We adjusted for confounders using inverse probability of treatment weighting (IPTW) and performed a logistic regression analysis to assess factors associated with serious infections, clinical remission, and treatment persistence.

Results

Eighty-three patients commencing ustekinumab and 124 commencing anti-TNF therapy were included. There was no difference in serious infection rates between anti-TNF agents (2.8%) and ustekinumab (3.1%) (P = .924) after propensity adjustment. Clinical remission rates were comparable at 6 months for ustekinumab (55.9%) and anti-TNF agents (52.4%) (P = .762). There was a significant reduction in HBI at 6 months in both groups. Treatment persistence was comparable between ustekinumab (90.6%) and anti-TNF agents (90.0%) at 6 months. Cox regression analysis did not show differences in treatment persistence (hazard ratio, 1.23; 95% confidence interval, 0.57-2.61; P = .594) and serious infection incidence (hazard ratio, 1.38; 95% confidence interval, 0.25-7.57; P = .709) by 6 months.

Conclusions

We observed comparable safety and effectiveness for ustekinumab and anti-TNF agents in treating elderly CD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedRemission InductionTreatment OutcomeFollow-Up StudiesInfliximab

Stichwörter der Autor:innen

Crohn’s diseaseanti-TNFeffectivenesselderlysafetyustekinumab

Substanzen

UstekinumabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsInfliximab

Autor:innen und Institutionen

  • Department Gastroenterology, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
  • Department of Internal Medicine, IRCCS San Matteo of Pavia, University of Pavia, Pavia, Italy.
  • Section of IBD, Division of Gastroenterology, Northern Care Alliance NHS Trust, Manchester, United Kingdom.
  • Manchester Academic Health Sciences, Division of Inflammation and Repair, Faculty of Medicine, Biology & Health, University of Manchester, Manchester, United Kingdom.
  • Department of Gastroenterology, Leeds University Teaching Hospital NHS Trust, Leeds, United Kingdom.
  • Department of Gastroenterology, Wirral University Teaching Hospital NHS Trust, Wirral, United Kingdom.

ORCID-Profile: Sreedhar Subramanian

Zitieren

APA

Gebeyehu, G. G., Broglio, G., Liu, E., Limdi, J. K., Selinger, C., Fiske, J., Razanskaite, V., Smith, P. J., Flanagan, P. K., & Subramanian, S. (2025). Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn’s Disease Patients. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae174

Vancouver

Gebeyehu GG, Broglio G, Liu E, Limdi JK, Selinger C, Fiske J, et al. Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn’s Disease Patients. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae174

BibTeX
@article{Gebeyehu2025,
  author = {Gebeyehu, Gerum Gashaw and Broglio, Giacomo and Liu, Eleanor and Limdi, Jimmy K and Selinger, Christian and Fiske, Joseph and Razanskaite, Violeta and Smith, Philip J and Flanagan, Paul K and Subramanian, Sreedhar},
  title = {Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn’s Disease Patients},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae174}
}
Kostenlos starten →